Literature DB >> 139204

Immunosuppressive activity of ascitic fluid from patients with cancer metastatic to the peritoneum.

A M Badger, S R Cooperband, V J Merluzzi, A H Glasgow.   

Abstract

We have examined the immunosuppressive effects of ascitic fluids from patients with advanced cancer metastatic to the peritoneum and compared them with noncancerous abdominal or pleural effusions, serum from cancer patients, or the proteins human serum albumin and bovine gamma-globulin. The ascitic fluids from cancer patients produce a nontoxic, dose-dependent suppression of DNA and protein synthesis of phytohemagglutinin-stimulated human peripheral blood lymphocytes. This suppression reached 100% with an ascitic protein concentration of 4 to 6 mg/ml, whereas control effusions, serum from cancer patients, or added extraneous proteins were not suppressive. Ascitic proteins also suppress the mixed lymphocyte reaction and the response of human peripheral blood lymphocytes to the antigen keyhold limpet hemocyanin, in vivo, the primary plaque-forming response to sheep red blood cells in mice could be suppressed, and this suppression was not due to antigenic competition.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 139204

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  6 in total

Review 1.  Need for immunologic stimulators during immunosuppression produced by major cancer surgery.

Authors:  W H Cole; L Humphrey
Journal:  Ann Surg       Date:  1985-07       Impact factor: 12.969

2.  A permeability-enhancing factor produced by tumor. The genesis of malignant effusions.

Authors:  R Stein-Werblowsky
Journal:  J Cancer Res Clin Oncol       Date:  1980       Impact factor: 4.553

3.  Immunologic enhancement of experimental metastasis in the rat.

Authors:  J R Starkey; S S Ristow; T L McDonald; J E Talmadge
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

Review 4.  Cancer cachexia: its correlations and causes.

Authors:  Harry Rubin
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-17       Impact factor: 11.205

5.  Role of a SER immune suppressor in immune surveillance.

Authors:  S K Oh; S Ross; J Walker; S Zeisel
Journal:  Immunology       Date:  1988-05       Impact factor: 7.397

6.  Inhibition of lymphocyte mitogenesis by factor(s) released from macrophages isolated from ascitic fluid of advanced ovarian cancer patients.

Authors:  B Sheid; J Boyce
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.